Wells Fargo lowered the firm’s price target on Concentra (CON) to $25 from $27 and keeps an Overweight rating on the shares. The firm is also updating its estimates to reflect Q4 results and Physicians Health Center deal. Out-year EBITDA estimates slightly raised, with core EBITDA growth better than previously modeled in 2025, Wells adds.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CON:
- Concentra Group Holdings: Strategic Acquisitions Bolster Growth and Justify Buy Rating
- Concentra price target raised to $26 from $24 at Goldman Sachs
- Concentra upgraded to Hold from Sell at Spin-Off Research
- Concentra price target raised to $26 from $25 at BofA
- Positive Outlook for Concentra Group Holdings: Buy Rating Reinforced by Strong Q4 Results and Strategic Acquisitions
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue